Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEN1-80E
- Development stage
- Unknown
- Lead developer
- Hawaii Biotech
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Administration
- Intramuscular, Subcutaneous
01
Overview
DEN1-80E is a recombinant subunit vaccine antigen consisting of a truncated envelope (E) glycoprotein from dengue virus serotype 1. It is designed as part of monovalent or tetravalent dengue vaccine formulations, where similar proteins from all four dengue serotypes are combined. The protein is produced recombinantly (commonly in Drosophila S2 cells), and formulated with adjuvants such as Alhydrogel or ISCOMATRIX to enhance immunogenicity. In preclinical and early clinical studies, DEN1-80E has been shown to induce neutralizing antibodies against DENV-1 and provide protection against viremia in animal models. Clinical trials have demonstrated that the vaccine induces modest but detectable neutralizing antibody responses in flavivirus-naïve adults, with good tolerability[5][6][1].
- Other names
- DEN1-80EDEN-1-80EDEN 1-80E
02
Targets
DENV-1 E (Dengue virus serotype 1 envelope protein)E (Tick-borne encephalitis virus envelope protein)
Beyond the preview
Go deeper on DEN1-80E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEN1-80E.